JAGX

-- -- --

From January 1, 2023 to December 31,2023 Common stock issued in At the Market offering, net of issuance and offering costs of $242 Common stock issued to Iliad in exchange of notes payable and accrued interest Common shares issued to Streeterville from conversion of Series H Preferred Stock Common shares issued to Irving from conversion of Series I Preferred Stock Common stock issued to Irving in exchange of notes payable and accrued interest Common shares issued to Irving from conversion of Series H Preferred Stock Common shares issued to from conversion of Series G Preferred Stock Common stock issued upon exercise of restricted stock units Common stock issued to other third party for services RSUs issued

From June 30, 2023 to September 30, 2023 Preferred shares issued to Irving in exchange of notes payable and accrued interest Common shares issued in At The Market offering, net of $65,000 offering costs Common shares issued to Streeterville from conversion of Series H Preferred Stock RSUs issued

From March 31, 2023 to June 30, 2023 Common stock issued in At the Market offering, net of issuance and offering costs of $147 Common stock issued to Irving in exchange of notes payable and accrued interest Common stock issued upon exercise of restricted stock units Common stock issued to third party for services

From January 1, 2023 to March 31, 2023 Shares issued to Irving in exchange of notes payable and accrued interest Shares issued to third party for services Shares issued in At the Market offering, net of issuance and offering costs of $30 Shares issued to Iliad in exchange of notes payable and accrued interest

A reverse stock split of the Company’s issued and outstanding Common Stock at a ratio of 1-for-75.

From June 30, 2022 to September 30, 2022 Shares issued to Streeterville in exchange of notes payable and accrued interest Shares issued in At the Market offering, net of issuance and offering costs of $3 Shares issued to Iliad in exchange of notes payable and accrued interest Shares issued to Synworld for services Shares issued to other third party for services Shares issued upon exercise of restricted stock units Shares issued upon exercise of stock options

From March 31,2022 to June 30,2022 Shares issued in At the Market offering, net of issuance and offering costs of 17,000 Shares issued to Iliad in exchange of notes payable and accrued interest Shares issued upon exercise of restricted stock units Shares issued to third party for services

From January 1, 2022 to March 31, 2022 Shares issued in At the Market offering, net of issuance and offering costs of $83 Shares issued to Iliad in exchange of notes payable and accrued interest Shares issued to third party for services

From January 1, 2021 to December 31, 2021 Shares issued on exercise of Series 1, Series 2, and 2019 Bridge Note Warrants Shares issued in PIPE financing Shares issued in At the Market offering, net of issuance and offering costs of $465 Shares issued in registered public offering, net of issuance and offering costs of $2,550 Shares issued in extinguishment of Exchange Note 2 Shares issued on exercise of Series 3 warrants Shares issued to Iliad in exchange of notes payable and accrued interest Shares issued on conversion of Napo merger common shares Shares issued upon exercise of stock options Shares issued to third party for services Fractional shares

From June 30, 2021 to September 30, 2021 Shares issued in PIPE financing Shares issued to third party for services Shares issued upon exercise of stock options Shares issued on conversion of Napo merger common shares Fractional shares

Jaguar Health, Inc. today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock (“Common Stock”), at an exchange ratio of 1-for-3, on Wednesday, September 8, 2021 (the “Effective Date”).

From March 31, 2021 to June 30, 2021 Shares issued in registered public offering, net of issuance and offering costs of $948 Shares issued to Iliad in exchange of notes payable and accrued interest Shares issued upon exercise of stock options Shares issued on conversion of Napo merger common shares

1.Common stock offered by the company 7,647,000 shares. 2.The number of shares of common stock to be outstanding after this offering is based on 129,671,263 shares of voting common stock and 2,020 shares of non-voting common stock outstanding as of April 26, 2021.

From January 1, 2021 To March 31, 2021 Shares issued on exercise of Series 1, Series 2, and 2019 Bridge Note Warrants Shares issued in PIPE financing Shares issued in At the Market offering, net of issuance and offering costs of $311 Shares issued in registered public offering, net of issuance and offering costs of $1,602 Shares issued in extinguishment of Exchange Shares issued on exercise of Series 3 warrants Shares issued on conversion of Napo merger common shares

1.Common stock offered by the company 4,437,870 shares of voting common stock. 2.The number of shares of common stock to be outstanding after this offering is based on 117,816,001 shares of voting common stock and 2,020 shares of non-voting common stock outstanding as of January 11, 2021.

from January 1, 2020 to December 31, 2020 Shares issued on conversion of Series 1, Series 2, and 2019 Bridge Note warrants Shares issued on exercise of Series 2 warrants and inducement offer conversion of Series B-1 convertible preferred stock Shares issued on conversion of Series 1, Series 2, and 2019 Bridge Note warrants, net of issuance costs of $461; May 2020 Shares issued on conversion of Series 1, Series 2, and 2019 Bridge Note warrants; June 2020 Shares issued on conversion of Series 3 warrants Shares issued on conversion of Series 1 and Series 2 warrants Shares issued to Atlas Sciences for settlement of Trial Delay Fee Shares issued on conversion of warrants of Atlas for settlement of Trial Delay Fee Shares issued in PIPE financing, net of issuance costs of $51 Shares issued in underwriter settlement agreement Conversion of Series B convertible preferred stock into common stock Conversion of Series B-2 convertible preferred stock into common stock Shares issued to Oasis as consideration under the March 2020 equity purchase agreement Shares issued to Oasis under the March 2020 equity purchase agreement, put option exercise, net of issuance costs of $13 Series A convertible preferred stock redeemed and Series C perpetual preferred issued under the Exchange transaction Stock dividend attributable to Series C perpetual preferred stock of $8 per share Shares issued to third party for services Shares issued to Sagard Capital in exchange of services Shares issued in exchange of CVP Exchange Notes Shares issued on conversion of warrants to Pacific Capital Management in exchange of promissory note Shares issued to PoC Capital in payment of contracted research fees Shares issued to Iliad in exchange of Royalty Interest Shares issued on exchange of Series C perpetual preferred stock Warrants issued and converted to common stock in exchange for Series C preferred stock Shares issue on exchange of Series D convertible preferred stock Conversion of non-voting common stock to voting common stock Shares issued in At The Market offering, net of offering costs of $78 Fractional shares Shares issued upon exercise of stock options

1.Common stock offered by the company 2,000,000 shares of Common Stock. 2.Common stock offered by the company 250,000 shares of Common Stock 2.The number of shares of common stock to be outstanding after this offering is based on 54,046,489 shares of voting common stock and 38,382 shares of non-voting common stock outstanding as of October 7, 2020.

From June 30, 2020 to September 30, 2020 Series A convertible preferred stock redeemed and Series C perpetual preferred issued under the exchange transaction Accretion to redemption value of redeemable preferred stock Stock dividend attributable to Series C perpetual preferred stock of $8 per share Shares issued on exercise of Series 3 warrants Shares issued on exercise of Series 1 and Series 2 warrants Shares issued to third party for services Shares issued in exchange of CVP Exchange Notes Fractional shares Shares issued upon exercise of stock options

From March 31, 2020 to June 30, 2020 Accretion to redemption value of redeemable preferred stock Shares issued on exercise of Series 1, Series 2, and 2019 Bridge Note warrants, net of issuance costs of $461; May 2020 Shares issued on conversion of Series 1, Series 2, and 2019 Bridge Note warrants; June 2020 Shares issued in Underwriter settlement agreement Conversion of Series B convertible preferred stock into common stock Shares issued to Oasis as consideration under the March 2020 equity purchase agreement Shares issued to Oasis under the March 2020 equity purchase agreement, put option exercise, net of issuance costs of $13 Shares issued to third party for services

From January 1, 2020 to March 31, 2020 Conversion of Series B-2 convertible preferred stock into common stock Shares issued on exercise of Series 1, Series 2, and 2019 Bridge Note warrants Shares issued on exercise of Series 2 warrants and inducement offer conversion of Series B-1 convertible preferred stock Issuance of common stock in PIPE financing, net of issuance costs of $51 Accretion to redemption value of redeemable preferred stock

From January 1, 2019 to December 31, 2019 Issuance of common stock to Oasis, put exercise Issuance of common stock to Oasis, registered offering Issuance of common stock in exchange of CVP Notes Issuance of common stock for payment of interest expense (Kingdon) Issuance of common stock in exchange of CVP Exchange Notes Issuance of Series B convertible preferred stock, net of offering costs of $875,184 Issuance of common stock in Class A Units, net Issuance of common stock upon conversion of Series B convertible preferred stock Fractional common stock shares repurchased Issuance of common stock for Tempesta Settlement, October 2019 Issuance of common stock upon exercise of Series 1 warrants, October 2019 Issuance of preferred stock to Ionic, October 2019 Issuance of preferred stock, October 2019 Issuance of common stock in exchange for services, October 2019 Issuance of common stock upon settlement of prepaid equity forward contracts, net, November 2019 Conversion of Series B convertible preferred stock into common stock, December 2019 Issuance of Series B-2 preferred stock in exchange for prepaid equity forward contracts and Jaguar Health common stock, December 2019 Issuance of common stock in PIPE Financing, December 2019

From March 31, 2019 to June 30, 2019 Issuance of common stock to Oasis, put exercise Issuance of common stock in exchange of CVP Notes Issuance of common stock in exchange of CVP Exchange Notes Fractional common stock shares repurchased

Jaguar Health, Inc. (NASDAQ: JAGX), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company will effect a reverse stock split of its issued and outstanding voting common stock (“Common Stock”), at an exchange ratio of 1-for-70 (the “Reverse Stock Split”), on Friday, June 7, 2019 (the “Effective Date”).

On April 1, 2019, the Company entered into another common stock purchase agreement (the “April CSPA”) with Oasis Capital relating to an offering (the “April Equity Line Offering”) of an aggregate of up to 20,000,000 shares (the “April Purchase Shares”) of the Company’s common stock, all of which are being offered in a primary offering consisting of an equity line of credit. Under the terms of the April CSPA, the Company has the right to “put,” or sell, the April Purchase Shares to Oasis Capital for an amount equalt to the product of (i) the number of April Purchase Shares set forth in the applicable put notice (minus the deposit and clearing fees associated with such purchase) and (ii) a fixed price of $0.28 per share or such other price agreed upon between the Company and Oasis Capital. The Company had the option to increase the equity line of credit by an additional 20,000,000 shares of Common Stock by notifying Oasis Capital at any time after the effective date of the April CSPA.

from December 31, 2017 to November 14, 2018 Issuance of preferred stock and common stock in a private investment in public entities March 2018 Issuance of common stock in a private investment in public entities with new investors March 2018 Issuance of common stock in a private investment in public entities with existing investors March 2018 Issuance of common stock in exchange for redemption of convertible debt Issuance of common stock in exchange for services March 2018 Issuance of common stock in exchange for payment of interest expense July 2018 Conversion of non-voting common stock to voting common stock July 2018 Issuance of common stock in lieu of interest July 2018 Issuance of common stock July 2018 Issuance of common stock in debt financing September 2018 Shares issued in S-1 offering, net of issuance costs of $1.9 million, October 2018 Shares issued from prepaid equity forward contracts, October 2018

From December 31, 2017 to September 30, 2018 Issuance of preferred stock and common stock in a private investment in public entities March 2018 Issuance of common stock in a private investment in public entities with new investors Issuance of common stock in a private investment in public entities with existing investors Issuance of common stock in exchange for redemption of convertible debt Issuance of common stock in exchange for services Issuance of common stock in exchange for payment of interest expense Conversion of non-voting common stock to voting common stock

From December 31, 2017 to June 30, 2018 Issuance of preferred stock and common stock in a private investment in public entities March 2018 Issuance of common stock in a private investment in public entities with new investors Issuance of common stock in a private investment in public entities with existing investors Issuance of common stock in exchange for redemption of convertible debt Issuance of common stock in exchange for services Issuance of common stock in exchange for payment of interest expense Conversion of non-voting common stock to voting common stock

The one for fifteen stock split.

From December 31, 2017 to April 9, 2018 Issuance of preferred stock and common stock in a private investment in public entities March 2018 Issuance of common stock in a private investment in public entities November 2017 Issuance of common stock in a private investment in public entities January 2018 Issuance of common stock in exchange for redemption of convertible debt Issuance of common stock in exchange for services Issuance of common stock in exchange for payment of interest expense

from December 31, 2016 to December 31, 2017 Issuance of common stock in association with a June 2016 private investment in public entities offering, net of offering costs of $72,710 Issuance of common stock in a private investment in public entities offering, net of offering costs of $6,000 June 2017 Issuance of common stock through a stock purchase agreement with a private investor, net of offering costs of $44,738 November 2017 Issuance of common stock in a private investment in public entities offering Issuance of common stock in the merger Issuance of common stock in a July 2017 CSPA Issuance of common stock in a follow-on offering registration statement October 2017, net of commissions and offering costs of $763,502 Conversion of non-voting common stock to common stock Issuance of common stock in exchange for warrants Issuance of common stock in exchange for vested restricted stock units Issuance of common stock in exchange for redemption of convertible debt Issuance of common stock in exchange for services Issuance of common stock—non-voting in the merger

from December 31, 2016 to September 30, 2017 Issuance of common stock associated with private investment in public entities offering, net of offering costs of $72,710 June 2016 Issuance of common stock in a private investment in public entities offering, net of offering costs of $6,000 June 2017 Issuance of common stock -voting in the Napo merger Issuance of common stock in a July 2017 CSPA Issuance of common stock -voting on exercise of warrants Issuance of common stock -voting in exchange for vested restricted stock units Issuance of common stock - non-voting in the Napo merger

On July 31, 2017, the Company filed a third amended and restated certificate of incorporation authorizing the Company to issue 250,000,000 shares of common stock $0.0001 par value and 50,000,000 of convertible non-voting common stock, $0.0001 par value per share.

from December 31, 2016 to June 30, 2017 Issuance of common stock associated with the June 2016 private investment in public entities offering, net of offering costs of $61,781 Issuance of common stock in a private investment in public entities offering, net of offering costs of $3,000 June 2017

from December 31, 2016 to March 31, 2017 Issuance of common stock in a private investment in public entities offering, net of offering costs of $7,632.

from December 31, 2015 to December 1, 2016 Issuance of common stock in a secondary public offering ,net of discounts and commissions of $373,011 and offering costs of $496,887 February 2016 Issuance of common stock in a private investment in public entities offering, net of offering costs of $105,398 June 2016. Issuance of common stock in a private investment in public entities offering October 2016 Issuance of common stock and equity warrants in a private investment in public entities offering, net of warrant liability of $700,001 and net of offering costs of $96,833 November 2016 Issuance of common stock in exchange for vested restricted stock units

From December 31, 2015 to September 15, 2016 Issuance of common stock in a secondary public offering, net of discounts and commissions of $373,011 and offering costs of $496,887 Issuance of common stock in a private investment in public entities offering, net of offering costs of $105,398 Issuance of common stock in exchange for vested restricted stock units

from December 31, 2015 to June 15, 2016 Issuance of common stock in a secondary public offering ,net of discounts and commissions of $373,011 and offering costs of $496,887. Issuance of common stock in a private investment in public entities offering, net of offering costs of $51,268. Issuance of common stock in exchange for vested restricted stock units

from December 31, 2015 to March 31, 2016 Issuance of common stock in a secondary public offering ,net of discounts and commissions of $373,011 and offering costs of $496,887 Issuance of common stock in exchange for vested restricted stock units

In February 2016, we completed a follow-on registration offering of our common stock. In connection with the offering, we issued 2,000,000 shares of our common stock at a price to the public of $2.50 per share.

from December 31, 2014 to December 31, 2015 Conversion of preferred stock into common stock upon initial public offering Issuance of common stock in initial public offering, net of discounts and commissions of $1,209,802, offering costs of $2,897,825 and offering costs in the form of common stock warrants of $400,400 Conversion of convertible notes into common stock upon initial public offering Issuance of common stock upon exercise of stock options

from December 31, 2014 to September 30, 2015 Conversion of preferred stock into common stock upon initital public offering Issuance of common stock in intial public offering, net of discounts and commissions of $1,209,802 and offering costs of $2,897,825 Conversion of convertible notes into common stock upon initial public offering Issuance of common stock upon exercise of stock options

from December 31, 2014 to June 30, 2015 Conversion of preferred stock into common stock upon initital public offering Issuance of common stock in intial public offering, net of discounts and commissions of $1,209,802 and offering costs of $2,897,825 Conversion of convertible notes into common stock upon initial public offering

1. a 1-for-1.5 reverse stock split of our common stock effected on October 27, 2014; 2. the conversion of all 3,015,902 outstanding shares of Series A preferred stock into 2,010,596 shares of common stock upon the closing of this offering;

From December 31, 2013 to October 28, 2014 Conversion of notes payable into common stock a 1-for-1.5 reverse stock split of our common stock effected on October 27, 2014

from December 31, 2013 to June 30, 2014 Issuance of redeemable convertible preferred stock, net Conversion of notes payable into common stock